Vivoryon - Positive Readthrough from Dona Readout (Sponsored Research, TP EUR 33, 10 pgs)
Top-line results from donanemab’s Ph3 TRAILBLAZE-ALZ2 was reported on May 3rd, where clearance of the N3pE plaques significantly slowed cognitive decline in early AD patients. Efficacy was stronger compared to our analysis of the other mAbs, most notably in patients with intermediate tau levels. There is clear positive readthrough to Vivoryon’s oral varo’ with validation on both the mechanism & clinical potential as varo’ blocks formation of both N3pE & pE-CCl2 plaques. Varo’ has a differentiated safety profile, setting it apart from the mAbs, which reported material rates of ARIA & cases of drug-related death. The oral dosing option also reduces treatment burden. A trial update from the Ph2 VIVA-MIND is expected in H223 and a final VIVIAD readout expected in Q124. In our view, a potential launch under Accelerated Approval is possible in 2025. We reiterate our PT of €33. There is 75% upside to our PT.For access to the full note and our initiation, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.